Tag: Otonomy Inc

All

Otonomy Announces Results of Phase 2a Trial for OTO-413

Otonomy, Inc announced positive top-line results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.

Otonomy Reports Positive Top-line Results for OTO-413
Otonomy Partners with Kyorin Pharmaceutical on Hearing Loss Compound
Otonomy Announces Positive Top-Line Results from Tinnitus Drug Trial
Otonomy Initiates Clinical Trial for Tinnitus Drug
Otonomy Announces Upcoming Presentations at 42nd ARO MidWinter Meeting
Otonomy Presents Data on OTO-413 Therapy for Hearing Loss

All

Webinar on Pediatric Chemo-Induced Hearing Loss to Be Held September 13

This half-day event follows the Food and Drug Administration’s (FDA) model for externally-led Patient Focused Drug Development meetings and serves to inform the agency’s regulatory decision-making in pediatric oncology.

Otonomy to Present at ARO Annual MidWinter Meeting
Otonomy Announces Plan to Focus on Development of Drug for Ménière’s Disease
Otonomy Announces Financial Updates
Otonomy Suspends Development of Drug to Treat Ménière’s Disease
Otonomy to Host Key Opinion Leader Meeting June 27
Auris Medical Holding AG and Otonomy Seek FDA Approval for Drugs to Treat Ear Disorders

All

Otonomy Enrolls Patients for Phase 2 Trial of OTO-104 for Prevention of Hearing Loss During Chemotherapy

Otonomy has announced the enrollment of the first patients in a Phase 2 clinical trial evaluating OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.

Drug Trial Results Offer Hope for Ménière’s, Tinnitus Patients
FDA Approves OTIPRIO for the Treatment of Children Undergoing Tympanostomy Tube Placement Surgery
New Drugs for Hearing Loss Expected in 5 Years
New York Times: New Drug Studies Target Ear and Balance Ailments
C&EN Publishes Article on Pharmaceutical Approaches to Hearing Treatment

Tag: Otonomy Inc

All

All

All

Sorry, No Posts Found